CAR-T cell therapy JCAR014 produces impressive response rates across a range of hematological malignancies.
By Rachael Lloyd, Analyst
16 June 2016
I am a disease analyst at Datamonitor Healthcare, specialising in oncology. I joined the team in September 2015 having p...
Read full bio
Patients with various relapsed/refractory hematological malignancies have demonstrated outstanding response rates to Juno Therapeutics’ CD19 CAR-T therapy, JCAR014, in a Phase I/II clinical trial (ClinicalTrials.gov identifier: NCT01865617). Ninety patients with relapsed/refractory CD19+ acute lymphoblastic leukemia (ALL) (n=36), non-Hodgkin’s lymphoma (NHL) (n=41) and chronic lymphocytic leukemia (CLL) (n=13) received lymphodepleting chemotherapy followed by infusion of a 1:1 ratio of CD8+:CD4+ CAR-T cells. Complete molecular remission was recorded in 94% of ALL patients and a complete response was achieved in 50% and 45% of relapsed/refractory NHL and CLL patients, respectively. Patients that were immunodepleted with cyclophosphamide fared worse than those treated with cyclophaphamide and fludarabine because the former group developed an immune response to the murine scFv of the CAR, reducing CAR-T cell persistence.
These results represent a significant step forward for Juno Therapeutics which has several CAR-T therapies in development for the treatment of hematological malignancies. However, overall survival and disease free survival data are expected to follow, and these results will be an important factor in determining the success of JCAR014 and other CAR-T therapies for the treatment of hematological cancers as disease recurrence still remains an issue.
Phase I/II data for JCAR014 in the treatment of hematologic cancers
Datamonitor Healthcare and Biomedtracker’s Mid-ASCO 2016 Weekend Update Report provides supplemental analyses on key abstracts and companies through the first three days of the 2016 ASCO meeting. Additional coverage through the rest of the meeting will be compiled in our post-meeting report.
Additionally, in conjunction with a Key Opinion Leader, several Informa analysts participated in a post-meeting webinar discussing the major developments of the conference and key take-aways. To view a recording of the webinar, click here.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>